Grass peptide immunotherapy cuts seasonal allergy symptoms

Grass peptide immunotherapy cuts seasonal allergy symptoms

(HealthDay)—Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) reduces seasonal allergy symptoms and is generally well tolerated, according to a study published online March 7 in Allergy.

Ralph Mösges, M.D., from the Institute of Medical Statistics, Informatics and Epidemiology in Cologne, Germany, and colleagues assessed the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over three weeks among 554 adults with grass pollen rhinoconjunctivitis. The participants were randomized in a 1:2 ratio to receive subcutaneous injections or placebo.

The researchers found that in the LPP group the mean reduction in combined symptom and medication score was significantly lower than the group during the peak period (P = 0.041) and over the entire pollen season (P = 0.029). Compared to the , the LPP group had reduced reactivity to a conjunctival provocation test (P < 0.001) and, during the season, a lower rhinoconjunctivitis quality of life global score (P = 0.005). In 10.5 percent of LPP-treated patients, mostly mild early systemic reactions (ESRs) were observed within 30 minutes. However, three patients with a medical history of asthma (<1 percent) experienced a serious ESR that resolved with rescue medication.

"LPP administered over three weeks before the grass significantly reduced seasonal symptoms, was generally safe and well tolerated," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including ASIT Biotech, which funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Allergy

Copyright © 2018 HealthDay. All rights reserved.

Citation: Grass peptide immunotherapy cuts seasonal allergy symptoms (2018, March 16) retrieved 28 March 2024 from https://medicalxpress.com/news/2018-03-grass-peptide-immunotherapy-seasonal-allergy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Booster allergen immunotx cuts symptoms in allergic rhinitis

3 shares

Feedback to editors